Dune has introduced normalized real-time data feeds for spot and perpetual decentralized exchange (DEX) trades across blockchain markets. This development aims to help institutional trading desks better compare and analyze fragmented market data on-chain. By providing consolidated and timely trade information, Dune enhances transparency and decision-making for professional traders operating in decentralized finance (DeFi). This move could improve market efficiency and support the growing demand for reliable blockchain market data.
The introduction of normalized real-time data feeds for decentralized exchange trades by Dune provides context for readers interested in blockchain market data. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 24, 2026 01:31 WIB: out of 50 priced major cryptocurrencies, 43 rose and 6 fell. Notable movers include YFI at Rp39.837.602 with a 3.00% increase and a Pluang order activity of 33% Sell / 67% Buy, UNI at Rp129.204 up 2.60% with 52% Sell / 48% Buy, and SAND at Rp942 down 2.60% with 60% Sell / 40% Buy.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
